Amgen (AMGN): No Conclusion on Sensipar's Role in Death, Still Working with FDA
Tweet
Share
E-mailGet Alerts AMGN Hot Sheet
Join SI Premium – FREE
Amgen, Inc. (NASDAQ: AMGN) says there is no conclusion on Sensipar's role in death outlined by the FDA. The company said it was still working with the FDA on Sensipar development.
Comments were made by a spokesperson via email to Bloomberg.
Comments were made by a spokesperson via email to Bloomberg.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FTC files amicus brief challenging Amgen's Enbrel patent acquisition
- Amgen (AMGN) PT Raised to $362 at Morgan Stanley
- Aggreko files for NYSE IPO under ticker AGKO
Create E-mail Alert Related Categories
Corporate News, FDA, Insiders' BlogSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
